Fermenta Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹133 Cr +1.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
FB

Fermenta Biotech Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Fermenta Biotech Q4 FY26: Revenue ₹547.8 Cr, PAT ₹18.6 Cr

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹122Cr
−13.1% YoY
−11.5% QoQ
Net profit
₹19Cr
−44.2% YoY
+54.7% QoQ
Margin
16.45%
−10 pp YoY
−1.7 pp QoQ

Based on Fermenta Biotech Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹478
Market cap₹1.4K Cr
P/E25.5

The short version

Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY - Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY - Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY - FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY - Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY - Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY - Green Chemistry Sales: ₹16 crore, up 126% YoY - Real estate value unlocking declined significantly (INR 45 crore in FY25 vs INR 2 crore in FY26) impacting headline figures - Q4/FY26 EBITDA: ₹25.1 crore, down 39% YoY (Page 5) - Q4/FY26 Profit after Tax (PAT): ₹18.6 crore, down 44% YoY (Page 5) - Operating margin: EBITDA margin held at 22.3% (Page 5) - Revenue for Q4/

From Fermenta Biotech Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY
  • Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY
  • Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY
  • FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY
  • Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY
  • Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY
  • Green Chemistry Sales: ₹16 crore, up 126% YoY

2 more points from Fermenta Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex for FY26 was INR 30 crore, up from INR 22 crore in FY25, focused on capacity readiness (Page 11).
  • Investing cash flow showed a net outflow of INR 43 crore in FY26, mainly on capacity additions (Page 11).
  • Capacity expansion driver mentioned: employee cost increased to 16% in FY26 from 15% in FY25, indicating headcount addition due to capacity growth (Page 12).

2 more points from Fermenta Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Fermenta Biotech Ltd Q4 FY26 results — key figures

Fermenta Biotech Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue122140-13.1%137-11.5%
Operating profit (EBITDA)2037-45.9%25-19.9%
Operating margin16.45%26.42%-10 pp18.17%-1.7 pp
Profit before tax2632-18.1%17+49.9%
Net profit (PAT)1933-44.2%12+54.7%
EPS (₹)6.5211.68-44.2%4.31+51.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fermenta Biotech Ltd Q4 FY26 results?

Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY - Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY - Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY - FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY - Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY - Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY - Green Chemistry Sales: ₹16 crore, up 126% YoY - Real estate value unlocking declined significantly (INR 45 crore in FY25 vs INR 2 crore in FY26) impacting headline figures - Q4/FY26 EBITDA: ₹25.1 crore, down 39% YoY (Page 5) - Q4/FY26 Profit after Tax (PAT): ₹18.6 crore, down 44% YoY (Page 5) - Operating margin: EBITDA margin held at 22.3% (Page 5) - Revenue for Q4/

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fermenta Biotech Ltd planning capital expenditure?

Capex for FY26 was INR 30 crore, up from INR 22 crore in FY25, focused on capacity readiness (Page 11).

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.